The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Abstract
PURPOSE: We have previously identified paclitaxel as an active single agent in the treatment of esophageal cancer. We performed a phase II trial of paclitaxel in combination with cisplatin and fluorouracil (5-FU), conventionally used chemotherapy for esophageal cancer. The antitumor response, toxicity, and survival of patients treated with the three-drug regimen were evaluated. PATIENTS AND METHODS: Sixty-one patients with advanced, surgically unresectable, or metastatic squamous cell or adenocarcinoma of the esophagus were treated. No prior chemotherapy was allowed. Thirty patients had adenocarcinoma and 31 patients had squamous cell carcinoma. The majority (47 patients; 77%) had metastatic disease and 14 patients (23%) had an unresectable primary or locally recurrent tumor. Patients received paclitaxel 175 mg/m2 by 3-hour infusion day 1; cisplatin 20 mg/m2 daily days 1 through 5, and 5-FU by continuous infusion at a dose of 1,000 mg/m2 daily days 1 through 5. Because of toxicity observed in the first 10 patients treated, the starting dose of 5-FU was subsequently reduced to 750 mg/m2 daily in the remaining patients. A planned attenuation of cisplatin to 15 mg/m2 daily was made after the first three cycles. Granulocyte colony-stimulating factor (G-CSF) was not routinely administered unless the patient had an episode of febrile neutropenia or prolonged grade 4 neutropenia. Treatment was recycled every 28 days. RESULTS: Sixty-one patients completed a median of five cycles, and 60 patients were assessable for response. Major responses were seen in 29 patients (48%; 95% confidence intervals, 35 to 61), which included seven complete responses (12%). Comparable response rates were seen for patients with adenocarcinoma (46%) and those with squamous carcinoma (50%), and for patients with metastatic disease (22 of 46 patients; 48%) and those with locally advanced disease (seven of 14 patients; 50%). A significantly higher complete response rate was observed in patients with squamous carcinoma (20%) compared with those with adenocarcinoma (3%; chi2 P=.04). The median duration of response was 5.7 months (range, 1 to 18.6 months). Median survival was 10.8 months (range, 1.5 to 25 months). Toxicity was severe but manageable with dose attenuation, and included 18% of patients with grade 3 neurologic toxicity. Twenty-eight patients (46%) required a dose attenuation for toxicity, and 42 of 275 treatment cycles (15%) required a dose attenuation. Twenty-nine patients (48%) required hospitalization for toxicity, which included 11 patients for neutropenic fever (18%). There were no treatment-related deaths. CONCLUSION: The combination of paclitaxel, cisplatin, and 5-FU has substantial antitumor activity in metastatic esophageal carcinoma, with a remarkable complete response rate noted in patients with squamous carcinoma. Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted. Given the toxicity associated with the current regimen, the optimal dose and schedule of paclitaxel in combination chemotherapy remain to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Cited by
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., & On behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, T. B. S. O. G. A. T. B. A. O. S. O. (2011) · Gut · doi:10.1136/gut.2010.228254 · Cited by 793
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1
Kitagawa, Y., Ishihara, R., Ishikawa, H., Ito, Y., Oyama, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawachi, H., et al. (2023) · Esophagus · doi:10.1007/s10388-023-00993-2 · Cited by 427
Esophageal and Esophagogastric Junction Cancers
Ajani, J. A., Barthel, J. S., Bentrem, D. J., D'Amico, T. A., Das, P., Denlinger, C. S., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0072 · Cited by 331
Self-citationAjani, J. A., Mansfield, P. F., Crane, C. H., Wu, T. T., Lunagomez, S., Lynch, P. M., Janjan, N., Feig, B., Faust, J., Yao, J. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.305 · Cited by 282
Self-citation
Metadata
- Authors
- Ilson, D. H., Ajani, J., Bhalla, K., Forastiere, A., Huang, Y., Patel, P., Martin, L., Donegan, J., Pazdur, R., Reed, C., & Kelsen, D. P.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-05
- Volume
- 16
- Issue
- 5
- Pages
- 1826-1834
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2223406810
- Cited by
- 204
- References
- 1
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. https://app.cochat.ai/papers/10.1200/jco.1998.16.5.1826
- The paper
- Ilson, D. H., Ajani, J., Bhalla, K., Forastiere, A., Huang, Y., Patel, P., Martin, L., Donegan, J., Pazdur, R., Reed, C., & Kelsen, D. P. (1998). Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.5.1826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.